摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-苄氧基-3-甲氧基苯乙酸 | 29973-91-9

中文名称
4-苄氧基-3-甲氧基苯乙酸
中文别名
4-苄氧基-3-甲氧苯基乙酸
英文名称
4-benzyloxy-3-methoxyphenylacetic acid
英文别名
2-[4-(benzyloxy)-3-methoxyphenyl]acetic acid;2-(3-methoxy-4-phenylmethoxyphenyl)acetic acid
4-苄氧基-3-甲氧基苯乙酸化学式
CAS
29973-91-9
化学式
C16H16O4
mdl
MFCD00185562
分子量
272.301
InChiKey
AYCIHUSEBJLTBF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    100-102 °C (lit.)
  • 沸点:
    440.1±35.0 °C(Predicted)
  • 密度:
    1?+-.0.06 g/cm3(Predicted)
  • 稳定性/保质期:

    遵照规定使用和储存,则不会分解。

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    20
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.187
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2918990090
  • WGK Germany:
    3

SDS

SDS:85bfbab27f471e2b083e349544828ed2
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Benzyloxy-3-methoxyphenylacetic acid
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 29973-91-9
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin irritation (Category 2), H315
Serious eye damage (Category 1), H318
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22, R37/38, R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

SECTION 3: Composition/information on ingredients
Substances
Formula : C16H16O4
Molecular Weight : 272,3 g/mol
CAS-No. : 29973-91-9
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Benzyloxy-3-methoxyphenylacetic acid
Acute Tox. 4; Skin Irrit. 2; Eye -
Dam. 1; STOT SE 3; H302,
H315, H318, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Benzyloxy-3-methoxyphenylacetic acid
Xn, R22 - R37/38 - R41 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: crystalline
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 100 - 102 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,869
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Inhalation: no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available



SECTION 15 - REGULATORY INFORMATION
N/A


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    4-苄氧基-3-甲氧基苯乙酸 在 palladium on activated charcoal 氢气 作用下, 以 乙醇 为溶剂, 生成 高香草酸
    参考文献:
    名称:
    Waehaelae, Kristiina; Hase, Tapio A., Journal of the Chemical Society. Perkin transactions I, 1991, # 12, p. 3005 - 3008
    摘要:
    DOI:
  • 作为产物:
    描述:
    高香草酸sodium carbonate 、 sodium hydroxide 作用下, 以 乙醇甲苯 为溶剂, 生成 4-苄氧基-3-甲氧基苯乙酸
    参考文献:
    名称:
    一种伊伐布雷定杂质的制备方法
    摘要:
    本发明公开了一种伊伐布雷定杂质的制备方法,具体包括分别以3‑羟基‑4‑甲氧基苯乙酸(式1a)和4‑羟基‑3‑甲氧基苯乙酸(式1b)为起始原料,经过多步反应得到伊伐布雷定的两个杂质,本发明的制备方法简单,纯度高,得到的杂质可以用于定性和定量的分析,从而提高伊伐布雷定的用药安全性。
    公开号:
    CN108424389A
点击查看最新优质反应信息

文献信息

  • Substituted Isoquinolinones and Quinazolinones
    申请人:BERGHAUSEN Joerg
    公开号:US20110230457A1
    公开(公告)日:2011-09-22
    The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH 2 or N—R 4 and X, R 1 , R 2 , R 4 , R 6 , R 7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    这项发明涉及公式(I)中的取代氮含有的双环杂环化合物,其中Z为CH2或N—R4,X、R1、R2、R4、R6、R7和n的定义如描述中所述。这类化合物适用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病变体。
  • 8-Heteroaryl xanthine adenosine A2B receptor antagonists
    申请人:——
    公开号:US20030207879A1
    公开(公告)日:2003-11-06
    The present invention relates generally to compounds of formula (IA): (IA) 1 the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as potent or selective A 2B adenosine receptor antagonists and their uses for treating asthma, autoimmune diseases and retinal vascular diseases.
    本发明总体上涉及公式(IA)的化合物:(IA)1,其制备方法、药物制剂及其在医学中的应用,作为强效或选择性的A2B腺苷受体拮抗剂,以及用于治疗哮喘、自身免疫疾病和视网膜血管疾病的用途。
  • Biosynthesis. Part 24. Speculative incorporation experiments with 1-benzylisoquinolines and a logical approach via C<sub>6</sub>–C<sub>2</sub>and C<sub>6</sub>–C<sub>3</sub>precursors to the biosynthesis of hasubanonine and protostephanine
    作者:Alan R. Battersby、Raymond C. F. Jones、Rymantas Kazlauskas、Craig W. Thornber、Somsak Ruchirawat、James Staunton
    DOI:10.1039/p19810002016
    日期:——
    Many possible 1-benzyltetrahydroisoquinolines have been examined as possible advanced precursors of the alkaloids hasubanonine (1) and protostephanine (2) in Stephania japonica plants, but none was incorporated significantly. Administration of various precursor molecules having only one aromatic ring, such as tyrosine, has demonstrated that both alkaloids are derived from two different C6–C2 biogenetic
    已经研究了许多可能的1-苄基四氢异喹啉类化合物,它们是Stephania japonica植物中生物碱hasubanonine(1)和protostephanine(2)的可能的高级前体,但没有明显掺入。施用仅具有一个芳香环的各种前体分子(例如酪氨酸)已证明这两种生物碱均来自两个不同的C 6 -C 2生物遗传单位。随后无法进一步引入1-苄基四氢异喹啉和双苯乙胺,这表明(a)改性的1-苄基异喹啉或(b)三加氧的C 6 –C 2中间体建筑模块。设计用于检查第一种可能性的前体,例如1-苄基-3,4-二氢异喹啉或1-苄基-1-羧基四氢异喹啉,未合并到(1)和(2)中,而两个3',4',5'-掺入三氧化的2-苯基乙胺。这些发现允许进一步描述对生物碱(1)和(2)的后续前体的需求。
  • Chemoselective Union of Olefins, Organohalides, and Redox-Active Esters Enables Regioselective Alkene Dialkylation
    作者:Tao Yang、Yi Jiang、Yixin Luo、Joel Jun Han Lim、Yu Lan、Ming Joo Koh
    DOI:10.1021/jacs.0c09922
    日期:2020.12.23
    tolerates a wide array of complex functionalities, and enables regiodivergent addition of two primary alkyl groups bearing similar electronic and steric attributes across aliphatic C═C bonds with exquisite control of site selectivity. Utility is underscored by the concise synthesis of bioactive compounds and postreaction functionalizations leading to structurally diverse scaffolds. DFT studies revealed
    可以在温和条件下一步生成多个 C(sp3)-C(sp3) 键的多组分催化过程,特别是那些使用廉价催化剂和底物的过程,在复杂分子合成的化学研究中备受追捧。在这里,我们公开了一种有效的催化还原方案,该方案化学选择性地将烯基酰胺与两种不同的脂肪族亲电试剂合并。起始材料很容易从稳定且丰富的原料中获得,并且产品以高达 >98:2 的区域异构体比例提供。目前的策略消除了敏感有机属试剂的使用,容忍了广泛的复杂功能,并且能够在脂族 C=C 键上区域发散地添加两个具有相似电子和空间属性的伯烷基,并精确控制位点选择性。生物活性化合物的简洁合成和反应后功能化导致结构多样化的支架强调了实用性。DFT 研究表明,区域化学结果源于原位生成的有机镍物种的正交反应性和化学选择性。
  • [EN] PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PHÉNYL-HÉTÉROARYLE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
    申请人:TRANSTECH PHARMA INC
    公开号:WO2011103091A1
    公开(公告)日:2011-08-25
    The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.
    本发明提供了式(I)的苯基-杂环芳基衍生物及其药学上可接受的盐。这些化合物在治疗RAGE介导的疾病,如阿尔茨海默病方面是有用的。本发明还涉及制备式(I)化合物及其药学上可接受的盐的方法,包括含有这些化合物的药物组合物,以及在治疗RAGE介导的疾病中使用这些化合物和/或药物组合物的用途。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯